在“用极低成本为个人定制健康与长寿方案”这一目标下，我重新组建了一个 10 人的跨学科顾问团，覆盖分子抗衰、成本控制、数字疗法、公共卫生与支付模式等关键环节，可帮助您在科学可行性、商业模式与大规模可负担性之间找到最优平衡。

## 选择原则概览

1. **深耕抗衰但关注普及**：挑选既在分子/细胞抗衰领域领衔，又公开倡导技术平价化的学者或企业家，例如 Sinclair 与 Barzilai 针对降低 NAD 和 Metformin 成本的研究。([Sinclair Lab](https://sinclair.hms.harvard.edu/research?utm_source=chatgpt.com "Research | The Sinclair Lab - Harvard University"), [American Federation for Aging Research](https://www.afar.org/tame-trial?utm_source=chatgpt.com "TAME - Targeting Aging with Metformin"))
    
2. **验证“低成本可复制”模式**：引入已在心脏手术、生活方式医学或健康保险中证明过大幅降本能力的实践者（如 Shetty 和 Ornish）。([Commonwealth Fund](https://www.commonwealthfund.org/publications/case-study/2017/nov/expanding-access-low-cost-high-quality-tertiary-care?utm_source=chatgpt.com "Narayana Health: Low-Cost, High-Quality Tertiary Care"), [Preventive Medicine Research Institute](https://pmri.org/research/cost-savings?utm_source=chatgpt.com "Outcomes & Cost-Savings - Preventive Medicine Research Institute"))
    
3. **利用 AI 与数字医疗规模化**：吸纳在 AI 药物发现、远程监测与数字干预领域具全球影响力者（Topol、Zhavoronkov、Kennedy）。([Scripps Research](https://www.scripps.edu/faculty/topol/?utm_source=chatgpt.com "Eric Topol, MD - Scripps Research"), [WIRED](https://www.wired.com/story/artificial-intelligence-drug-discovery?utm_source=chatgpt.com "Where Are All the AI Drugs?"), [NUS Medicine](https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/?utm_source=chatgpt.com "Brian Kennedy - Department of Biochemistry - NUS Medicine"))
    
4. **从支付与政策端保证落地**：配置健康经济学与医保支付体系专家（Goldman、Hsiao、Fried），为成本压缩与全民可及度提供制度方案。([USC Leonard Davis School of Gerontology](https://gero.usc.edu/faculty/dana-goldman-phd/?utm_source=chatgpt.com "Dana Goldman, PhD - USC Leonard Davis School of Gerontology"), [Fairbank Center for Chinese Studies](https://fairbank.fas.harvard.edu/person/william-hsiao/?utm_source=chatgpt.com "William Hsiao - Fairbank Center for Chinese Studies"), [Mailman School of Public Health](https://www.publichealth.columbia.edu/profile/linda-p-fried-md?utm_source=chatgpt.com "Linda P. Fried, MD, MPH"))
    

## 专家组与分工

| 角色定位                | 推荐人                                     | 贡献亮点                                                                                                                                                                                                                                                                                                                                                                                                                                       | 关键讨论议题                  |
| ------------------- | --------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ----------------------- |
| 分子抗衰 & NAD 途径       | **Dr. David Sinclair**（哈佛）              | 领导 NAD⁺ 提升分子研究并开展人体试验([Sinclair Lab](https://sinclair.hms.harvard.edu/research?utm_source=chatgpt.com "Research \| The Sinclair Lab - Harvard University"))                                                                                                                                                                                                                                                                                | 开源化 NAD 补充剂、专利路径与价格压缩   |
| 临床试验 & Metformin 抗衰 | **Dr. Nir Barzilai**（TAME 牵头人）          | 将廉价药 Metformin 用于抗衰大型临床([American Federation for Aging Research](https://www.afar.org/tame-trial?utm_source=chatgpt.com "TAME - Targeting Aging with Metformin"), [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC5943638/?utm_source=chatgpt.com "Metformin as a Tool to Target Aging - PMC"))                                                                                                                                             | 用常用药物“再定位”构建极低成本干预组合    |
| 生活方式医学              | **Dr. Dean Ornish**（PMRI）               | 其心脏逆转项目曾帮医保每例节省 3 万美元([PubMed](https://pubmed.ncbi.nlm.nih.gov/19809349/?utm_source=chatgpt.com "Costs of cardiac rehabilitation and enhanced lifestyle modification ..."), [Preventive Medicine Research Institute](https://pmri.org/research/cost-savings?utm_source=chatgpt.com "Outcomes & Cost-Savings - Preventive Medicine Research Institute"))                                                                                    | 把可证据化的饮食/运动方案转为 SaaS 订阅 |
| 低成本医疗模式             | **Dr. Devi Shetty**（Narayana Health）    | 通过“工厂化心外科”把手术费降至传统 1/4([Commonwealth Fund](https://www.commonwealthfund.org/publications/case-study/2017/nov/expanding-access-low-cost-high-quality-tertiary-care?utm_source=chatgpt.com "Narayana Health: Low-Cost, High-Quality Tertiary Care"))                                                                                                                                                                                         | 复制到慢病管理中心的流程与分层定价       |
| 数字医疗 & AI           | **Dr. Eric Topol**（Scripps）             | 发表 1300+ 篇，推动 AI + 可穿戴个性化医疗([Scripps Research](https://www.scripps.edu/faculty/topol/?utm_source=chatgpt.com "Eric Topol, MD - Scripps Research"))                                                                                                                                                                                                                                                                                         | 利用智能手环/语音监测实现持续个体化迭代    |
| AI 药物发现 & 成本压缩      | **Alex Zhavoronkov**（Insilico Medicine） | 用生成式 AI 缩短新药设计周期、降低成本([Insilico Medicine](https://insilico.com/?utm_source=chatgpt.com "Insilico Medicine: Main"), [WIRED](https://www.wired.com/story/artificial-intelligence-drug-discovery?utm_source=chatgpt.com "Where Are All the AI Drugs?"))                                                                                                                                                                                       | 把 AI 模型迁移到营养补充及微生态配方    |
| 机制研究 & 亚洲可复制        | **Dr. Brian Kennedy**（NUS Ageing）       | 聚焦衰老生物学与在东南亚转化应用([NUS Medicine](https://medicine.nus.edu.sg/bch/faculty/brian-kennedy/?utm_source=chatgpt.com "Brian Kennedy - Department of Biochemistry - NUS Medicine"))                                                                                                                                                                                                                                                                | 在中低收入市场建立实验验证与推广路径      |
| 健康经济学               | **Prof. Dana Goldman**（USC）             | 提出“Netflix 式”药品订阅模型([USC Leonard Davis School of Gerontology](https://gero.usc.edu/faculty/dana-goldman-phd/?utm_source=chatgpt.com "Dana Goldman, PhD - USC Leonard Davis School of Gerontology"))                                                                                                                                                                                                                                        | 探索月度包费+低自付的个人长寿服务       |
| 公共卫生 & 健康长寿         | **Dr. Linda Fried**（哥大）                 | 领衔“健康长寿”研究，倡导防止衰弱([Mailman School of Public Health](https://www.publichealth.columbia.edu/profile/linda-p-fried-md?utm_source=chatgpt.com "Linda P. Fried, MD, MPH"), [WHOOP](https://www.whoop.com/in/en/thelocker/podcast-329-live-longer-and-stronger-with-dr-linda-fried/?srsltid=AfmBOor6Dp5KUO3Bj-nQx5_P5gfhxZlTvRW_EcORhLevN7yjGt-M1cFG&utm_source=chatgpt.com "Live Longer and Stronger – Avoiding Frailty with Dr. Linda Fried")) | 将社区互助、目的感等非药物因子纳入方案     |
| 医保与制度设计             | **Prof. William Hsiao**（哈佛）             | 40 年为多国设计低成本 UHC 模式([Fairbank Center for Chinese Studies](https://fairbank.fas.harvard.edu/person/william-hsiao/?utm_source=chatgpt.com "William Hsiao - Fairbank Center for Chinese Studies"), [The Harvard Crimson](https://www.thecrimson.com/article/2011/12/7/hsia-health-care-vermont/?utm_source=chatgpt.com "HSPH Professor Helps with Vermont Health Care Reform \| News"))                                                       | 设计按结果付费与微保费互助基金模型       |

## 建议的讨论架构

### 1. “百元级抗衰”最小可行产品（MVP）

- **Sinclair + Barzilai**：筛选三种可批量采购的 OTC 级干预（如低剂量 Metformin、NMN 替代物、维生素 D / K2 组合），评估 3 个月生物年龄变化。
    
- **Topol**：用可穿戴设备收集睡眠、心率变异等数据作实时反馈。
    

### 2. 大幅压缩单位服务成本

- **Shetty + Ornish**：建立“批量化评估—远程指导—自动随访”流水线，把教练/医生时长降至传统 20%。
    
- **Goldman + Hsiao**：设计“会员费 + 成果激励返现”模型，确保用户粘性与现金流平衡。
    

### 3. 规模化与地域扩展

- **Kennedy + Fried**：将方案在中等收入国家进行 A/B 试点，引入社区互助与目的感干预，以文化适配降低依从性成本。
    
- **Zhavoronkov**：开放 API 接口让第三方开发者为不同人群（如糖尿病、抑郁症高风险群）定制配方，形成生态。
    

## 落地操作要点

1. **共识文件**：先输出 5 页白皮书，明确“成本 < 现行市场 30%”的衡量指标。
    
2. **分层股权/咨询费**：核心科学家授予期权，其余专家按成果结算现金顾问费，降低前期支出。
    
3. **季度滚动评估**：每季度更新干预组合与成本数据，Topol 负责报告算法；Hsiao 评估医保对接可能性。
    

通过以上配置，您将获得“从实验室到大规模平价化”全链条的顶级指引，并在一次闭门工作坊内即可明确下一阶段的实验设计、成本结构与融资/政策通道。祝项目早日迈向可负担、可复制的长寿健康服务！